Swedish Medical AI Startup Tandem Health Secures $100 Million Funding Boost
Stockholm, Monday 14 September 2026
On 14 September 2026, Tandem Health secured $100 million to scale its clinical AI platform, which already supports over 10,000 healthcare organisations across 14 European countries.
Scaling the Clinical Workflow OS
The substantial $100 million Series B funding round, executed via the issuance of convertible preferred stock, marks a pivotal moment for Tandem Health [1][2]. The Stockholm-headquartered clinical AI startup plans to transition from its current state as an AI-based documentation assistant into a comprehensive, AI-based operating system designed to manage entire clinical workflows [2]. This expansion is supported by rapid market adoption: as of September 2026, Tandem’s technology is utilised by more than 10,000 healthcare organisations across 14 European countries [2]. This represents a doubling of its user base since March 2026, when the company reported integrations with over 100 electronic health record systems and a footprint of 5,000 organisations [2].
High Growth Amid Scaleup Realities
Tandem Health’s financial trajectory highlights both the rapid scalability of SaaS platforms and the capital-intensive nature of early-stage AI ventures. The company’s revenue grew from 2.7 million SEK in 2024 to 61.3 million SEK in 2025, representing an astronomical increase of 2170.37% [2]. To support this operational expansion, the company’s workforce grew from six employees to 31 over the same period, a increase of 416.667% [2]. However, in line with its status as a high-growth scaleup, Tandem is not yet profitable, reporting an operating loss of approximately 77.5 million SEK and a net loss of 84.6 million SEK for the fiscal year 2025 [2].
Geopolitical Capital and the Battle with US Giants
The funding round was led by the Scaleup Europe Fund, an initiative managed by the Swedish private equity firm EQT AB [1][2]. The fund, which aims to raise €5 billion in total—bolstered by a €1 billion commitment from the European Commission—was established specifically to provide high-growth European technology companies with home-grown capital, reducing their reliance on Silicon Valley funding during international expansion [2]. This European backing is critical as Tandem faces fierce competition from heavily funded US rivals, including Abridge, which secured a valuation of $5.3 billion in 2025, Ambience Healthcare, which raised $243 million in 2025, and Suki, with cumulative funding of $165 million by 2025 [2].
EQT’s Strategic Momentum in Deep Tech
For EQT, which reported managing €270 billion in assets under management at the end of 2025, this transaction represents a continuation of an aggressive investment drive [1]. Only days earlier, on 8 September 2026, EQT participated in a $450 million funding round for space technology company The Exploration Company GmbH and acted as a co-investor in a €3 billion funding round for French AI pioneer Mistral AI SAS [1]. These major deals followed the completion of EQT’s own 1.45 billion kronor share buyback programme on 8 September 2026 [1]. Currently, EQT’s portfolio management is weighted heavily towards real estate and infrastructure funds at 38.3%, with other sectors accounting for 1.8%, and the remaining 59.9% allocated across other fund strategies [1].
A Test Case for European Tech Sovereignty
Tandem Health represents the Scaleup Europe Fund’s first known investment in the clinical AI sector, following its inaugural transaction in August 2026, which backed satellite operator ICEYE in a $1 billion funding round, and its subsequent investment in Mistral AI [2]. The transaction also saw strong support from existing backers, including Northzone Ventures, Amino Collective, Visionaries Club, and Kinnevik AB [1][2]. Kinnevik, which held an approximate 12% stake in Tandem valued at 329 million SEK at the end of Q1 2026, would mathematically contribute 12 million USD if investing strictly pro rata in this round, though individual investor allocations remain unconfirmed [2]. The ultimate market valuation of Tandem following this round remains undisclosed, leaving industry analysts to watch closely as the firm attempts to establish a dominant European healthcare platform [2].